Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P).
BACKGROUND
The PORPUS-P is a short questionnaire for measuring prostate-specific quality of life (QoL), which was designed in Canada for use in prostate cancer (PC) patients. We aimed to generate a German version and compare PORPUS-P scores of German reference men from the general population, and German and Canadian patients with newly diagnosed PC who were scheduled to receive radical prostatectomy (RP) or radiotherapy (RT).


METHODS
The study sample consisted of 988 reference men, 121 German and 66 Canadian PC patients scheduled for RT, and 371 German and 68 Canadian PC patients scheduled for RP. All men completed the PORPUS-P (German postal questionnaire, Canada personal interview). Data were gathered from PC patients before the start of therapy.


RESULTS
Canadian patients were better educated than the German patients, and fewer were retired. Patients scheduled to receive RT were older and more were retired. German RT patients had lower D'Amico risk scores and pre-treatment Gleason scores than RP patients, and Canadian RT patients had higher pre-treatment PSA than RP patients. Urinary and sexual dysfunction were seen in PC patients (especially RT patients), but were also common in the German reference men. Crude mean PORPUS-P scores differed statistically significant between German RT and RP and Canadian RP and RT patients, with RT patients having higher QoL scores. The differences in age-adjusted mean PORPUS-P scores between reference men and RP patients were not clinically significant, while RT patients had (clinically) significantly lower scores than the reference men.


CONCLUSIONS
The German translation of the PORPUS-P appears to be a short and feasible tool for assessing prostate-specific QoL. Although we found a similar response pattern, Canadian and German PC patients scheduled to receive RT or RP rated their pre-treatment quality of life on different levels, which reveals the need for national reference data. Problems in several QoL domains exist before treatment, and differ between PC patients scheduled for RT and RP.
Waldmann
Annika
A
Institute of Cancer Epidemiology, University Luebeck, Beckergrube 43-47, 23552 Luebeck, Germany. Annika.Waldmann@krebsregister-sh.de
Rohde
Volker
V
Bremner
Karen
K
Krahn
Murray
M
Kuechler
Thomas
T
Katalinic
Alexander
A
D000368:Aged; D002170:Canada; D003131:Combined Modality Therapy; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000523:psychology* / Q000532:radiotherapy* / Q000601:surgery; D011594:Psychometrics; D011788:Quality of Life; D011795:Surveys and Questionnaires; D014175:Translating; D016896:Treatment Outcome; D044465:White People / Q000523:psychology
Int J Cancer. 2005 Aug 20;116(2):291-6
15800919
Qual Life Res. 2007 Dec;16(10):1665-75
17912614
Eur J Cancer. 2008 Mar;44(4):572-8
18221866
Neurourol Urodyn. 2000;19(3):259-71
10797583
Qual Life Res. 1996 Dec;5(6):555-67
8993101
Cancer. 2007 Jul 1;110(1):196-202
17546575
J Clin Oncol. 1998 Jan;16(1):139-44
9440735
Cancer. 2007 Jun 1;109(11):2239-47
17455209
J Clin Epidemiol. 2005 May;58(5):466-74
15845333
Eur J Cancer. 2001 Jul;37(11):1345-51
11435063
Asian J Androl. 2009 May;11(3):283-90
19349948
Qual Life Res. 2007 Apr;16(3):509-22
17091359
Cancer. 2003 Dec 1;98(11):2335-43
14635067
J Chronic Dis. 1987;40(5):373-83
3558716
J Urol. 2008 Apr;179(4):1354-60; discussion 1360-1
18289596
J Sex Med. 2008 Apr;5(4):919-927
18371045
Urol Res. 2004 Aug;32(4):283-9
15057494
Radiat Oncol Investig. 1999;7(3):178-85
10406060
JAMA. 1993 Jul 7;270(1):83-90
8510302
Urology. 1999 Sep;54(3):509-16
10475363
Int J Impot Res. 2007 Mar-Apr;19(2):183-8
16885992
J Clin Epidemiol. 2000 Sep;53(9):920-30
11004418
J Urol. 2005 Dec;174(6):2105-10
16280737
J R Soc Med. 2003 Sep;96(9):442-8
12949200
J Urol. 2006 Dec;176(6 Pt 1):2443-7
17085125
Prostate Cancer Prostatic Dis. 2007;10(1):52-9
17102801